Dr. Reddy's Launches Sildenafil Tablets

by Benzinga Staff
November 19, 2012 6:24 AM | 1 min read

20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.

Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Sildenafil Tablets (20 mg), a bioequivalent generic version of REVATIO® (Sildenafil) Tablets in the US market on November 16, 2012, following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy's ANDA for Sildenafil Tablets. The REVATIO® brand had U.S. sales of approximately $338.67 Million for the most recent twelve months ending September 2012 according to IMS Health*. Dr. Reddy's Sildenafil Tablets in 20 mg are available in 90 count bottle sizes. Disclaimer This press release includes forward-looking statements, See full press release

20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: NewsGuidanceContractsManagementGlobal

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.